Holen Sie sich die Stockscreener-App
1.31
2.96%
-0.04
Handel nachbörslich:
1.33
0.02
+1.53%
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga Japan
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
Live Pliant Therapeutics, Inc. (PLRX) Technical Analysis - Traders Union
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction for 2026, 2030-2040 - tradersunion.com
If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan
Pliant Therapeutics Launches New $50 Million ATM Program - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) files $300M shelf; $50M ATM with Leerink - Stock Titan
Pliant Therapeutics launches $50M at-the-market equity program, terminates prior sales agreement - TradingView
Pliant Therapeutics (NASDAQ: PLRX) shifts to new $50M at-the-market program - Stock Titan
Quarterly Recap: Is Pliant Therapeutics Inc subject to activist investor interestPortfolio Gains Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Sentiment Recap: Is Pliant Therapeutics Inc still a buy after recent gains2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Is Pliant Therapeutics Inc benefiting from interest rate changesWeekly Profit Recap & AI Enhanced Trading Signals - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR By Investing.com - Investing.com South Africa
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR - Investing.com Australia
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Investing News Network
AACR 2026 to feature Pliant Therapeutics Phase 1 PLN-101095 results at major symposium - Traders Union
Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting - TradingView
Pliant Therapeutics Announces Upcoming Presentation of - GlobeNewswire
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f - Bitget
Portfolio Shifts: Is Pliant Therapeutics Inc benefiting from interest rate changes2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Prosight Management Cuts Stake in Pliant Therapeutics - National Today
Prosight Management LP Has $30,000 Position in Pliant Therapeutics, Inc. $PLRX - MarketBeat
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - The Globe and Mail
Oppenheimer Remains a Hold on Pliant Therapeutics (PLRX) - The Globe and Mail
Pliant Therapeutics (PLRX): Canaccord Genuity Adjusts Price Targ - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK) - The Globe and Mail
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
Pliant Therapeutics 10‑K — No Revenue; Net Loss $2.43 EPS on $149.3M Net Loss - TradingView
PLRX: PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
BRIEF-Pliant Therapeutics Q4 Net Income USD -23.577 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - ChartMill
Cancer drug PLN-101095 shows 4 responses, Pliant speeds up trials - Stock Titan
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - The Globe and Mail
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics - Barchart.com
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):